|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:address
|
499 Illinois Street, San Francisco, CA 94158, USA
|
|
gptkbp:CEO
|
gptkb:George_Scangos
gptkb:Marianne_De_Backer
|
|
gptkbp:collaboratedWith
|
gptkb:Alnylam_Pharmaceuticals
gptkb:Biogen
gptkb:Bill_&_Melinda_Gates_Foundation
GlaxoSmithKline
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:developedBy
|
vaccines
monoclonal antibodies
antiviral therapies
|
|
gptkbp:focusesOn
|
immunology
infectious diseases
|
|
gptkbp:founded
|
2016
|
|
gptkbp:foundedBy
|
gptkb:Charles_Rice
gptkb:George_Scangos
gptkb:Herbert_Virgin
gptkb:Herbert_W._Virgin
gptkb:Jeffrey_Bluestone
gptkb:Robert_Nelsen
gptkb:Skip_Virgin
gptkb:John_Cox
gptkb:Vicki_Sato
|
|
gptkbp:headquartersLocation
|
gptkb:San_Francisco,_California,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
October 2019
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:marketCap
|
multi-billion USD (varies)
|
|
gptkbp:notable_executive
|
gptkb:George_Scangos
gptkb:Marianne_De_Backer
|
|
gptkbp:notableProduct
|
gptkb:Sotrovimab
|
|
gptkbp:numberOfEmployees
|
over 400
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:researchInterest
|
gptkb:COVID-19
gptkb:HIV
gptkb:hepatitis_B
gptkb:influenza
tuberculosis
malaria
|
|
gptkbp:SotrovimabIndication
|
gptkb:COVID-19
|
|
gptkbp:stockSymbol
|
VIR
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:VIR
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.vir.bio/
|
|
gptkbp:bfsParent
|
gptkb:SoftBank
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vir Biotechnology
|